Loading
A phase 2 trial of Vusolimogene oderparepvec and Pembrolizumab in Angiosarcoma, run by Varun Monga, MBBS, now recruiting.
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma is a phase 2 interventional study registered as NCT06898970 by Varun Monga, MBBS, with 18 participants planned, started 2026-01-09 and due to reach its primary completion in 2029-10-31. Interventions recorded: Vusolimogene Oderparepvec (VO), Pembrolizumab. Conditions recorded: Angiosarcoma, Angiosarcoma, Adult.
Linked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Angiosarcoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vusolimogene oderparepvec, Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Shares Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/